Author

admin

Browsing

President Donald Trump kicked off the week with a major breakthrough brokering a ceasefire agreement between Israel and Hamas, and closed out the week seeking to make progress on the next global conflict: Ukraine. 

Trump met with Israeli lawmakers in the Knesset on Monday, before heading to Egypt where he met with leaders there as well as Qatar, Turkey and other regional powers. The president urged countries in the region to ‘put the old feuds and bitter hatreds behind us.’

‘At long last, we have peace in the Middle East, and it’s a very simple expression, peace in the Middle East,’ Trump told reporters in Sharm el-Sheikh, Egypt.

‘We’ve heard it for many years, but nobody thought it could ever get there. And now we’re there,’ Trump said. 

The peace deal in the Middle East includes a provision to return the hostages that were still in captivity within 72 hours of Hamas signing off on the deal. It also called for Israeli forces to withdraw its troops and a complete disarmament of Hamas.

Now, Trump has said that he will set his sights on resolving the conflict between Russia and Ukraine. Trump spoke with Russian President Vladimir Putin on Thursday, and met with Ukrainian President Volodymyr Zelenskyy Friday at the White House. 

While Trump said that there is momentum to solve the conflict on the heels of the peace deal in the Middle East, there is ‘tremendous bad blood’ between Putin and Zelenskyy that is stalling a resolution. 

‘They have tremendous bad blood,’ Trump told reporters. ‘It’s really is what is holding up I think a settlement. I think we are going to get it done, and we have to make it long-lasting, as I said in the Middle East, everlasting.’ 

‘The Middle East is a much more complicated situation. You know, we had 59 countries involved, and every one of them agreed. And it’s, you know, it’s sort of amazing. Most people didn’t think that was doable. This is going to be something I really believe that’s going to get done. I had a very good talk yesterday with President Putin. I think he wants to get it done,’ Trump said. 

Meanwhile, Zelenskyy said that Trump has a big opportunity to make headway on mediating an end to the conflict. 

‘President Trump has really showed for the world that he can manage a ceasefire in the Middle East. And that’s why I hope that he will do this. And we will also have such big success. For Ukraine, it’s a big chance, and I hope that President Trump can manage it,’ Zelenskyy said Friday. 

This post appeared first on FOX NEWS

President Donald Trump recently awarded late Turning Point USA founder and CEO Charlie Kirk the Presidential Medal of Freedom just over one month after the activist was assassinated. Kirk was outspoken about his conservative and pro-life views, and his legacy has inspired a new wave of activism.

Shawn Carney, the president and CEO of 40 Days for Life, praised President Donald Trump as ‘the most pro-life president we’ve ever had,’ telling Fox News Digital that pro-life Americans were delighted to see the president honor Kirk.

‘It was so beautiful to see him honor Charlie,’ Carney said. ‘He represented freedom, and there would be no pro-life movement without free speech. Free speech is what 40 Days for Life is built on, it’s what the pro-Life dialogue is built upon. It’s [what] Charlie gave his life for, and it was really, really beautiful for all pro-life Americans to see him honored with the highest honor we have in our nation.’

Kirk was known for participating in debates across the country and the globe, often confronting his harshest critics. Carney believes that Kirk’s willingness to go into tough arenas as well as his approachable and ‘authentic’ nature drew young people to him and the pro-life movement.

‘Charlie was open and was honest, and he was also humble and willing to talk to you,’ Carney told Fox News Digital, adding that being approachable, as Kirk was, is crucial in pro-life activism.

‘So many people have been hurt by abortion. So many people feel strongly in support of reproductive rights. And you just can’t go in and yell or say you’re going to burn in hell. You have to approachable, you have to use reason, you can’t be afraid to share your faith, as Charlie wasn’t,’ he added.

Carney said that 40 Days for Life has seen an uptick in interest, particularly among young activists, in the wake of Kirk’s assassination.

‘His tragic assassination was just two weeks before we kicked off one of our largest fall 40 Days for Life campaigns around the world,’ Carney said. ‘Over 700 cities participating, and we saw a huge uptick, a 36% increase in participation. We had so many young people come out… who knew who Charlie Kirk was, and were inspired by him to participate in 40 Days for Life, who then brought their parents out to pray at our vigils.’

He recalled one young woman — who he did not name — who said she was ‘so afraid’ to participate in pro-life activism prior to Kirk’s death. Carney noted that despite the ‘horrible images’ of the assassination, many felt empowered and compelled to speak up about their beliefs.

‘You thought the opposite would happen, that she’d be more afraid and others would be more afraid, but that didn’t happen,’ he said. ‘It literally inspired her to overcome years of fear.’

Carney also spoke about a TPUSA chapter leader whose mother tried to talk her son out of participating in either TPUSA or 40 Days for Life. The young man apparently told his mother that Charlie would have wanted him to speak out and not to run from culture wars.

When asked what Kirk’s message to pro-life activists would be if he were still alive, Carney said it would be to not give up. Carney added that he has heard newcomers inspired by Kirk say they believe that the TPUSA founder would want them to be outspoken and not to ‘cower.’

‘Right now in our culture, there’s a lot of reasons to be afraid, we can’t give in to them, we have to go out, we have to speak the truth and love, and that is what changes hearts and minds, and that’s the best way we can honor Charlie,’ Carney told Fox News Digital.

This post appeared first on FOX NEWS

The U.S. Department of State on Saturday warned there are ‘credible reports’ that Hamas may break the peace agreement with a ‘planned attack’ on Palestinian civilians. 

‘This planned attack against Palestinian civilians would constitute a direct and grave violation of the ceasefire agreement and undermine the significant progress achieved through mediation efforts,’ the department said in a statement on social media. ‘The guarantors demand Hamas uphold its obligations under the ceasefire terms.’

The statement concluded, ‘The United States and the other guarantors remain resolute in our commitment to ensuring the safety of civilians, maintaining calm on the ground, and advancing peace and prosperity for the people of Gaza and the region as a whole.’

A ceasefire between Israel and Hamas went into effect last weekend after two years of war in the region following the Oct. 7, 2023, attacks in southern Israel. 

On Monday, the 20 remaining surviving Israeli hostages were returned to Israel per the agreement, but more than a dozen remains of hostages who were killed are still under Hamas control. 

The State Department added that ‘measures will be taken to protect the people of Gaza and preserve the integrity of the ceasefire’ if Hamas proceeds with the attack. 

On Thursday, President Donald Trump issued a warning on Truth Social after footage circulated online showing Hamas fighters executing Palestinians in Gaza City’s main square. 

‘If Hamas continues to kill people in Gaza, which was not the deal, we will have no choice but to go in and kill them,’ he wrote.

According to Reuters, at least 33 people were executed by Hamas in recent days in what officials described as a campaign to ‘show strength’ after the ceasefire. Israeli sources say most of those killed belonged to families accused of collaborating with Israel or supporting rival militias.

Trump later clarified that U.S. troops would not go into Gaza. 

‘It’s not going to be us,’ he told reporters. ‘We won’t have to. There are people very close, very nearby that will go in and they’ll do the trick very easily, but under our auspices.’

Fox News’ Efrat Lachter and the Associated Press contributed to this report. 

This post appeared first on FOX NEWS

Former Vice President Kamala Harris said her onetime boss, former President Joe Biden, made a ‘big mistake’ by not inviting Tesla CEO Elon Musk to a 2021 White House event on electric vehicles. 

In August 2021, Biden hosted an EV event at the White House with executives from General Motors, Ford and Stellantis, but Musk was not invited, despite Tesla being the nation’s leading EV manufacturer. 

‘I write in the book that I thought it was a big mistake to not invite Elon Musk when we did a big EV event,’ Harris told Fortune Editor-in-Chief Alyson Shontell on Tuesday at the news outlet’s Most Powerful Women Summit in Washington, D.C., referring to her memoir, ‘107 Days,’ in which she criticized Biden for initially running for re-election despite his health struggles.

‘I mean, here he is, the major American manufacturer of extraordinary innovation in this space,’ Harris said of Musk, who is also the CEO of SpaceX.

Musk’s snub was widely viewed as an effort to support the United Auto Workers and organized labor overall, since Tesla plants are not unionized. Harris wrote in her book that she believed Biden was ‘sending a message about Musk’s anti-union stance’ but that she thought excluding him as the top player in the field ‘simply doesn’t make sense.’

Then–White House Press Secretary Jen Psaki said the event featured ‘the three largest employers of the United Auto Workers,’ emphasizing that Tesla’s workers are not unionized.

Pressed on whether Musk’s snub was punishment for his workers not being unionized, Psaki told reporters: ‘I’ll let you draw your own conclusion.’

The Biden administration defended inviting only those automakers, calling them key partners in the president’s push for union jobs.

Harris said that presidents should ‘put aside political loyalties’ when it comes to recognizing technological innovation.

‘So, I thought that was a mistake, and I don’t know Elon Musk, but I have to assume that that was something that hit him hard and had an impact on his perspective,’ she said.

Musk did appear to take offense after he was not invited to the event, taking numerous jabs at Biden.

‘Yeah, seems odd that Tesla wasn’t invited,’ Musk wrote at the time on social media.

A month later, he said the Biden administration appeared to be ‘controlled by unions’ and was ‘not the friendliest administration.’

After Musk learned Tesla would not be invited, administration officials offered an apology, according to The Wall Street Journal. Biden aides later attempted to soothe things over, but tensions remained.

Harris’ comments on Tuesday mirrored a passage from her new book in which she wrote that the Biden administration’s move not to include Tesla was a mistake and that it appeared to alienate Musk, who later became one of current President Donald Trump’s top financial backers.

‘Musk never forgave it,’ she wrote.

Musk later endorsed Trump in the 2024 election and contributed roughly $300 million toward Republican campaign efforts. 

This post appeared first on FOX NEWS

Vince Lanci of Echobay Partners explains what’s driving silver’s record-setting price run.

According to Lanci, who is also a professor at the University of Connecticut and publisher of the GoldFix newsletter on Substack, the London market is facing a liquidity crisis as nations that would typically sell or lend their silver choose to keep the metal at home.

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

  • MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.

  • New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025.

  • Next-generation therapy CRD-38 for heart failure funded through to clinical development, with partnership discussions advancing with leading pharmaceutical companies.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (‘Cardiol’ or the ‘Company’), a clinical-stage life sciences company advancing late-stage, anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the successful completion of a private placement offering (the ‘Offering’) of units (‘Units’) for net proceeds of US$11 million. The initial closing of US$10 million has been completed, with the remaining US$1 million to close on Monday, October 20, 2025.

‘As recruitment in our pivotal Phase III MAVERIC trial gains momentum, with several prominent centers across the U.S. now enrolling patients, we are pleased to have secured a direct investment of US$11 million to strengthen our balance sheet and accelerate the development of our novel heart failure drug, CRD-38, based on the recently reported findings from our ARCHER trial,’ said David Elsley, President and CEO of Cardiol Therapeutics. ‘Topline results from our ARCHER trial demonstrated a significant reduction in LV mass-marking the first evidence of structural and remodeling improvement in patients with myocarditis. This landmark finding represents our second clinical validation in inflammatory heart disease and establishes a key translational link to data published earlier this year in the Journal of the American College of Cardiology, which demonstrated the beneficial effects of the active pharmaceutical ingredient or API in CardiolRx on cardiac structure, inflammation, and fibrosis in a model of heart failure. The ARCHER findings support pursuing an additional Orphan Drug Designation for CardiolRx in myocarditis and advancing the development of our next-generation CRD-38 formulation, which delivers the same API via subcutaneous administration, to target the broader heart failure market. Notably, blockbuster drugs that reduce LV mass have been shown to lower heart failure-related death and hospitalization, underscoring the clinical potential of Cardiol’s differentiated anti-inflammatory mechanism to address a large unmet need in heart failure, where five-year mortality rates still exceed 50%.’

Under the Offering, the Company sold a total of 11 million Units at a price of US$1.00 per Unit. Each Unit consists of one Class A common share of the Company (a ‘Common Share‘) and one-half of one Common Share purchase warrant. Each whole warrant entitles the holder to acquire one additional Common Share at an exercise price of US$1.35 for a period of 24 months from the date of issuance. The warrants include an acceleration provision, allowing the Company to advance their expiry to the 30th day following the issuance of a news release if the daily volume-weighted average trading price of the Common Shares exceeds US$2.00 for five consecutive trading days. Proceeds from the Offering provide cash resources that are anticipated to support operations into the third quarter of 2027.

The securities have not been registered under the United States Securities Act of 1933, as amended (the ‘U.S. Securities Act‘), or any U.S. state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the ‘United States’ or ‘U.S. persons’ (as such terms are used in Regulation S under the U.S. Securities Act), absent registration under the U.S. Securities Act and all applicable U.S. state securities laws or in compliance with an exemption therefrom. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Certain insiders of the Company participated in the Offering. Such participation is considered to be a ‘related-party transaction’ within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (‘MI 61-101‘). The Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related-party participation in the Offering as the fair market value (as determined under MI 61-101) of the subject matter of, and the fair market value of the consideration for, the transaction, insofar as it involved interested parties, did not exceed 25% of the Company’s market capitalization (as determined under MI 61-101).

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company advancing late-stage, anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small molecule drug candidate, CardiolRx, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, which includes recurrent pericarditis.

The ARCHER Program (NCT05180240) comprises the completed Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age.

Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure-a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion annually.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:

This news release contains ‘forward-looking information’ within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are ‘forward-looking information’. Forward-looking information contained herein may include, but is not limited to statements regarding the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx, the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation intended for use in heart failure, the Company’s presentation and publication of the comprehensive ARCHER trial data, the Company’s belief that results from the ARCHER trial provide compelling clinical proof of concept for CardiolRx and strongly support advancing the clinical development of CardiolRx and CRD-38 for the treatment of inflammatory cardiac disorders including cardiomyopathies, heart failure, and myocarditis, and statements regarding the expected length and scope of funding for the Company’s development plans as a result of the Offering. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.

For further information, please contact:
Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270946

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

The Government of Ontario started taking applications for resource development projects under its “One Project, One Process” framework on Friday (October 17).

The new process, which Ontario lawmakers introduced in the spring, promises to streamline and reduce the permitting time for selected projects by at least half, introducing a dedicated office to consolidate applications. Under the current system, the permitting process can add up to 15 years to a project’s development cycle, the government stated.

In addition to supporting Ontario’s mining industry, the new framework is also a reaction to policy shifts in the United States under the Trump administration, as his tariff policy affects the Ontario and Canadian economies.

“With President Trump taking direct aim at our economy, it has never been more important to protect Ontario jobs and build the mines that will power our future,” said Stephen Lecce, Minister of Energy and Mines.

The new policy is similar to the national one introduced by Prime Minister Mark Carney in September. That program, which created the Major Projects Office, is geared to support investment and permitting for projects deemed to be in the national interest. The initiative was part of his election platform earlier in the year in response to Trump’s tariffs on imports of Canadian goods.

In a speech to the Peterson Institute of International Economics on Thursday (October 16), Bank of Canada Governor Tiff Macklem stated that Canada’s growth outlook remains “soft.”

He identified several trends that are affecting Canadian and global economies. The first is a slowing of global trade that began in 2010, which then accelerated as Trump increased tariff rates to the highest levels since the 1930s.

The second is a shift away from the US as the world’s largest trading hub, as supply chains strengthen in China and Europe, creating new hubs there. Macklem also noted that, while the US remains dominant in global finance, investors have expressed uncertainty due to its declining trade position and increasing debt load.

For Canada, Macklem said the tariffs have affected cross-border trade and stymied investment into Canadian industries, weakening gross domestic product growth.

Although it’s uncertain if the Bank of Canada will cut its rate when it makes its next policy decision on October 29, Macklem said, “Monetary policy cannot undo the damage of tariffs.” Instead, he suggested that Canada needs to lower barriers to interprovincial trade and focus on projects that increase the export of Canadian goods overseas.

South of the border, Federal Reserve Chairman Jerome Powell gave a speech on Tuesday (October 14) to the National Association of Business Economics in Philadelphia. In his remarks, he said the outlook for the jobs market and inflation has not changed since September, and signaled the likelihood of another rate cut when the Federal Open Market Committee meets on October 28 and 29.

In the days following Powell’s remarks, the price of gold surged to a new record high of US$4,379.13 on Thursday, and silver rose to a new record of US$54.40 per ounce. Both have since retreated, but remain elevated.

For more on what’s moving markets this week, check out our top market news round-up.

Markets and commodities react

Canadian equity markets were down this week.

The S&P/TSX Composite Index (INDEXTSI:OSPTX) lost 0.71 percent over the week to close Friday at 30,108.48.

The S&P/TSX Venture Composite Index (INDEXTSI:JX) fared worse, ending the week down 3.85 percent at 965.58. The CSE Composite Index (CSE:CSECOMP) also fell this week, shedding 5.33 percent to close out the week at 179.76.

The gold price set another new record, reaching an intraday high of US$4,379.13 per ounce in early morning trading Friday EST before retreating to US$4,252.69 by Friday’s close. Ultimately, gold was up 5.82 percent over the week.

The silver price also gained significantly this week, again breaking its own all-time high in early trading Friday when it reached US$54.47 per ounce. However, it had pulled back US$51.76 by 4:00 p.m. EDT Friday, posting a weekly gain of 3.46 percent.

The copper price was flat on the week, down just 0.2 percent to US$5.03 per pound.

The S&P Goldman Sachs Commodities Index (INDEXSP:SPGSCI) fell 2.23 percent to end Friday at 539.84.

Top Canadian mining stocks this week

How did mining stocks perform against this backdrop?

Take a look at this week’s five best-performing Canadian mining stocks below.

Stocks data for this article was retrieved at 4:00 p.m. EDT on Friday using TradingView’s stock screener. Only companies trading on the TSX, TSXV and CSE with market caps greater than C$10 million are included. Mineral companies within the non-energy minerals, energy minerals, process industry and producer manufacturing sectors were considered.

1. JZR Gold (TSXV:JZR)

Weekly gain: 112.77 percent
Market cap: C$28.95 million
Share price: C$0.50

JZR Gold is a gold company with exposure to the Vila Nova gold project, located in Amapá, Brazil, through a joint venture royalty agreement with the project’s operator, ECO Mining Oil & Gaz Drilling and Exploration.

JZR received a 50 percent net profit interest in the Vila Nova project following the completion of payments totaling US$6 million to ECO in January 2023. The funds were used to advance the project and construct an 800 metric ton per day bulk sampling gravimetric mill at the site.

According to JZR, the funding is considered a loan and will be “repaid to the Company from the proceeds of the sale of any products, prior to the distribution of any profits.”

The project holds approximately 9 million metric tons of gold tailings grading an average of 2.47 grams per metric ton (g/t) gold from historic operations. The companies plan to reprocess the tailings to generate near-term cash flow that will fund further exploration at the site, anticipating production of 2 kilograms of gold per day.

Shares gained this week alongside the October 14 news that ECO produced the first gold concentrate from the Vila Nova gold project’s mill. JZR said that ECO has begun to stockpile material at the mill site as it continues testing and optimization, with the goal of improving efficiency and increasing throughput.

2. Austral Gold (TSXV:AGLD)

Weekly gain: 90 percent
Market cap: C$75.37 million
Share price: C$0.095

Austral Gold is a gold production company operating two mines in Latin America.

Its Guanaco – Amancaya mine complex in Chile is its primary operation, hosting a 1,500 metric ton per day milling circuit, a 3,000 metric ton per day crushing circuit and a heap leaching processing plant. In 2024, the complex produced 15,138 ounces of gold and 37,154 ounces of silver.

Austral’s other operation is the Casposo – Manantiales complex in Argentina, which hosts a 1,100 metric ton per day mill and a dry-stack tailings facility. The mine had been on care and maintenance since 2019, during which time Austral worked on exploration at the site, along with its refurbishment plan to restart operations.

Shares in Austral rose this week following a pair of announcements on Tuesday.

The first was a report that Austral has resumed production at Casposo, currently sourcing material from the existing stockpiles. The company said it plans to transition to open-pit mining and is in negotiations with a contractor to finalize an agreement.

The company produced 230 gold equivalent ounces of doré during the commissioning phase, which began in December 2024, according to the release. It expects Casposo to produce 4,000 to 6,000 gold equivalent ounces during Q4.

In the other release, Austral provided an updated mineral reserve estimate for Casposo reporting proven and probable gold contained to be 80,000 ounces of gold and 3.28 million ounces of silver with average grades of 1.31 g/t gold and 58.52 g/t silver from 2.15 million metric tons of ore.

3. Resouro Strategic Metals (TSXV:RSM)

Weekly gain: 88.64 percent
Market cap: C$29.14 million
Share price: C$0.415

Resouro Strategic Metals is a polymetallic exploration and development company working to advance its mineral properties in Brazil.

Its Tiros rare earth metals and titanium project is located in Minas Gerais, Brazil, and comprises 28 mineral rights covering an area of 497 square kilometers.

According to a May 2025 technical report, the site hosts a measured and indicated resource of 1.4 billion metric tons of ore grading 12 percent titanium dioxide and 4,000 parts per million of total rare earth content.

The company also owns the Novo Mundo gold project located in the Alta Floresta gold province in Central Brazil. It consists of three licenses totaling 167 square kilometers.

On Tuesday, Resouro provided an update to its ongoing private placement, noting that it had received subscription agreements and expects to close in the next week.

4. Nio Strategic Metals (TSXV:NIO)

Weekly gain: 75 percent
Market cap: C$16.24 million
Share price: C$0.175

Nio Strategic Metals is an exploration company working to advance its assets in Québec, Canada.

Its primary focus has been on its Oka rare earth and critical minerals project. The property hosts a past-producing niobium mine and several nearby mineralized zones.

According to the project page, Oka’s total measured and indicated resource is 10.63 million metric tons of ore at an average grade of 0.65 percent niobium oxide.

While the company did not release any news this week, shares in Nio Strategic Metals rose significantly.

5. Boron One (TSXV:BONE)

Weekly gain: 71 percent
Market cap: C$14.92 million
Share price: C$0.06

Boron One is an exploration company focused on advancing its Piskanja project located near Belgrade, Serbia.

The asset hosts two primary densely mineralized zones with gently undulating borate beds. The company was initially granted its exploration license in 2010, with the exclusive right to apply for a mining license.

In a preliminary economic assessment for the project released in June 2022, Boron One, then named Erin Ventures, reported an economic case with an after-tax, net present value of US$524.9 million with an internal rate of return of 78.7 percent and a payback period of 12 months.

It also provided a mineral resource statement that demonstrated a measured and indicated resource of 2.36 million metric tons of boric oxide from 6.87 million metric tons of ore with an average grade of 34.36 percent boric oxide.

The most recent news from the project came on September 26 when the company provided an update on its application for a mining license, noting the Ministry of Mining has requested amendments to the company’s application before it can be approved.

Boron One said it is preparing the revised version “as quickly as possible.”

FAQs for Canadian mining stocks

What is the difference between the TSX and TSXV?

The TSX, or Toronto Stock Exchange, is used by senior companies with larger market caps, and the TSXV, or TSX Venture Exchange, is used by smaller-cap companies. Companies listed on the TSXV can graduate to the senior exchange.

How many mining companies are listed on the TSX and TSXV?

As of May 2025, there were 1,565 companies listed on the TSXV, 910 of which were mining companies. Comparatively, the TSX was home to 1,899 companies, with 181 of those being mining companies.

Together, the TSX and TSXV host around 40 percent of the world’s public mining companies.

How much does it cost to list on the TSXV?

There are a variety of different fees that companies must pay to list on the TSXV, and according to the exchange, they can vary based on the transaction’s nature and complexity. The listing fee alone will most likely cost between C$10,000 to C$70,000. Accounting and auditing fees could rack up between C$25,000 and C$100,000, while legal fees are expected to be over C$75,000 and an underwriters’ commission may hit up to 12 percent.

The exchange lists a handful of other fees and expenses companies can expect, including but not limited to security commission and transfer agency fees, investor relations costs and director and officer liability insurance.

These are all just for the initial listing, of course. There are ongoing expenses once companies are trading, such as sustaining fees and additional listing fees, plus the costs associated with filing regular reports.

How do you trade on the TSXV?

Investors can trade on the TSXV the way they would trade stocks on any exchange. This means they can use a stock broker or an individual investment account to buy and sell shares of TSXV-listed companies during the exchange’s trading hours.

Article by Dean Belder; FAQs by Lauren Kelly.

Securities Disclosure: I, Dean Belder, hold no direct investment interest in any company mentioned in this article.

Securities Disclosure: I, Lauren Kelly, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

This week was marked by strong, event-driven volatility across the tech sector.

Market moves were shaped by artificial intelligence (AI) infrastructure announcements, semiconductor earnings, signals of macroeconomic stress and escalating tensions between the US and China.

Effects of the US government shutdown, coupled with renewed trade tensions between the world’s largest tech markets, weighed on global equities. Quarterly results from regional banks eased earlier concerns about credit risks after Zions Bancorp (NASDAQ:ZION) and Western Alliance (NYSE:WAL) disclosed loan issues related to apparent fraud.

Wall Street ultimately saw weekly gains, despite a midweek selloff that impacted high-value, high-risk sectors.

Hardware and infrastructure were the core positive contributors in the tech sector, reflecting the ongoing AI supercycle investment theme fueled by chip production and data center buildouts.

Semiconductor stocks were the standout performers, boosted by record earnings reports from Taiwan Semiconductor Manufacturing Company (TSMC) (NYSE:TSM) on Tuesday (October 14) and ASML Holding (NASDAQ:ASML) on Wednesday (October 15). Broadcom (NASDAQ:AVGO) and NVIDIA (NASDAQ:NVDA) also rose alongside TSMC, contributing to PHLX Semiconductor Sector’s (INDEXNASDAQ:SOX) 1.2 percent rebound on Thursday (October 16).

Advanced Micro Devices’ (NASDAQ:AMD) deal with Oracle (NYSE:ORCL) to deploy 50,000 GPUs, which was announced the same day as TSMC’s earnings, added a competitive dynamic that sparked selective volatility among chipmakers; at the same time, it underscored strong AI-driven hardware demand across the sector.

In consumer hardware, Apple’s (NASDAQ:AAPL) product launch was notable, but not the primary market mover.

Data centers also had a big impact, highlighted by Microsoft’s (NASDAQ:MSFT) US$14 billion Texas AI data center partnership with Nscale, and Brookfield Asset Management’s (TSX:BAM,NYSE:BAM) US$5 billion investment in Bloom Energy’s (NYSE:BE) fuel cell technology for powering AI-focused data centers. Oracle is forecasting acceleration in its AI data center business, indicating expanding hardware-backed infrastructure demand

Software and cloud-native company movements were more mixed, with gains from Salesforce (NYSE:CRM), but declines from others like Meta Platforms (NASDAQ:META) and Palantir Technologies (NASDAQ:PLTR).

3 tech stocks that moved markets this week

1. Broadcom (NASDAQ:AVGO)

Broadcom shares surged nearly 10 percent on Monday (October 13) after OpenAI announced a multi-year agreement to co-develop custom AI GPUs. The collaboration will focus on deploying 10 gigawatts of custom AI accelerators designed by OpenAI and built by Broadcom, with deployment set to start in H2 2026 and continue through 2029.

Later, multiple reports emerged citing individuals claiming that OpenAI is also partnering with Arm Holdings (NASDAQ:ARM) to produce custom CPUs to work alongside its Broadcom co-designed chip.

Shares of Arm also advanced by over 11 percent.

2. Advanced Micro Devices (NASDAQ:AMD)

Oracle and AMD also announced a major partnership this week, where Oracle will deploy 50,000 AMD-powered MI450 GPUs in its cloud infrastructure starting in the third quarter of 2026, with plans for ongoing expansion.

AMD’s share price rose by over 9 percent on the news, with the deal creating competitive pressure for rival chipmakers like NVIDIA. Meanwhile, Oracle shares declined by almost 7 percent on Friday (October 17) after the firm’s CEO, Clay Magouryk, provided an upbeat projection to analysts, indicating that the deployment of 50,000 AMD-powered MI450 GPUs will significantly accelerate Oracle’s AI business growth.

However, analysts highlighted the potential for a significantly high CAPEX, possibly leading to negative free cashflow totaling more than US$26 billion over the next three fiscal years.

3. Salesforce (NYSE:CRM)

Shares of Salesforce rose by almost 4 percent on Thursday after the company announced a revenue target of US$60 billion by 2030 during its Investor Day at Dreamforce event on Wednesday.

Salesforce plans to achieve this ambitious target through accelerated adoption of AI-powered cloud platforms and ongoing innovation in enterprise software services, as well as expanded use of generative AI across its CRM, analytics, and automation suites.

Broadcom, Salesforce and AMD performance, October 14 to 17, 2025.

Chart via Google Finance.

Tech ETF performance

This week, the iShares Semiconductor ETF (NASDAQ:SOXX) advanced by 1.94 percent, while the Invesco PHLX Semiconductor ETF (NASDAQ:SOXQ) saw a weekly gain of 1.66 percent.

The VanEck Semiconductor ETF (NASDAQ:SMH) increased by 1.59 percent.

These modest gains occurred against a backdrop of heightened volatility, indicating ongoing optimism in the long-term growth of the semiconductor industry.

Other tech market news

            Tech news to watch next week

            Next week brings quarterly earnings from major tech firms Tesla (NASDAQ:TSLA) and IBM (NYSE:IBM) on October 22, followed by Intel (NASDAQ:INTC) and Amazon (NASDAQ:AMZN) on October 23.

            Any new developments in US-China relations, potential technology export restrictions or antitrust actions could significantly affect tech stock performance. Market watchers will also be on the lookout for any indication of an end to the US government shutdown.

            Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

            This post appeared first on investingnews.com

            /NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/

            finlay minerals ltd. (TSXV: FYL,OTC:FYMNF) (OTCQB: FYMNF) (‘Finlay’ or the ‘Company’) is pleased to announce that it has closed its non-brokered private placement (the ‘Private Placement’), previously announced on October 6, 2025, consisting of the issuance of: (i) 10,633,999 flow-through units of the Company (each, a ‘FT Unit’) at a price of $0.15 per FT Unit, and (ii) 883,000 non-flow-through units of the Company (each, a ‘NFT Unit’) at a price of $0.13 per NFT Unit, for aggregate gross proceeds to the Company of $1,709,890.

            Each FT Unit is comprised of one common share of the Company issued on a flow-through basis under the Income Tax Act (Canada) (a ‘FT Share‘) and one-half of one non-flow-through common share purchase warrant (each whole warrant, a ‘Warrant‘). Each Warrant is exercisable by the holder thereof to acquire one non-flow-through common share of the Company (a ‘NFT Share‘) at an exercise price of $0.25 per NFT Share until October 17, 2027.

            Each NFT Unit is comprised of one NFT Share and one Warrant with identical terms to the Warrants underlying the FT Units.

            The Company intends to use the gross proceeds of the Private Placement for exploration of the Company’s SAY, JJB and Silver Hope properties, and for general working capital purposes, as more particularly described in the offering document for the Private Placement. The Company will use the gross proceeds from the issuance of FT Shares to incur ‘Canadian exploration expenses’ and qualify as ‘flow-through critical mineral mining expenditures’, as such terms are defined in the Income Tax Act (Canada).

            The Private Placement was conducted pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions and in reliance on the Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption. The securities issued to purchasers in the Private Placement are not subject to a hold period under applicable Canadian securities laws. The Private Placement is subject to final approval of the TSX Venture Exchange.

            The Company paid aggregate cash finder’s fees of $96,550.78 and issued 648,358 non-transferable finder warrants (each a ‘Finder Warrant‘) to arm’s length finders of the Company, as compensation for identifying purchasers in the Private Placement. Each Finder Warrant entitles the holder thereof to purchase one NFT Share at an exercise price of $0.25 per NFT Share until October 17, 2027. The Finder Warrants and the NFT Shares issued on exercise thereof are subject to a hold period expiring on February 18, 2026 in accordance with applicable securities laws.

            This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements thereunder.

            About finlay minerals ltd.

            Finlay is a TSXV company focused on exploration for base and precious metal deposits through the advancement of its ATTY, PIL, JJB, SAY and Silver Hope Properties; these properties host copper-gold porphyry and gold-silver epithermal targets within different porphyry districts of northern and central BC. All of the properties are located in areas of recent copper-gold porphyry discoveries.

            Finlay trades under the symbol ‘FYL’ on the TSXV and under the symbol ‘FYMNF’ on the OTCQB. For further information and details, please visit the Company’s website at www.finlayminerals.com 

            On behalf of the Board of Directors,

            Robert F. Brown,
            Executive Chairman of the Board

            Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

            Forward-Looking Information: This news release includes certain ‘forward-looking information’ and ‘forward-looking statements’ (collectively, ‘forward-looking statements’) within the meaning of applicable Canadian securities legislation. All statements in this news release that address events or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, although not always, identified by words such as ‘expect’, ‘plan’, ‘anticipate’, ‘project’, ‘target’, ‘potential’, ‘schedule’, ‘forecast’, ‘budget’, ‘estimate’, ‘intend’ or ‘believe’ and similar expressions or their negative connotations, or that events or conditions ‘will’, ‘would’, ‘may’, ‘could’, ‘should’ or ‘might’ occur. All such forward-looking statements are based on the opinions and estimates of management as of the date such statements are made. Forward-looking statements in this news release include statements regarding, among others, the final approval for the Private Placement from the TSXV and the planned use of proceeds for the Private Placement. Although Finlay believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include the ability to obtain regulatory approval for the Private Placement, the state of equity markets in Canada and other jurisdictions, market prices, exploration successes, and continued availability of capital and financing and general economic, market or business conditions. These forward-looking statements are based on a number of assumptions including, among other things, assumptions regarding general business and economic conditions, the timing and receipt of regulatory and governmental approvals, the ability of Finlay and other parties to satisfy stock exchange and other regulatory requirements in a timely manner, the availability of financing for Finlay’s proposed transactions and programs on reasonable terms, and the ability of third-party service providers to deliver services in a timely manner. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements, and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. Finlay does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future or otherwise, except as required by applicable law. 

            SOURCE finlay minerals ltd.

            View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2025/17/c8773.html

            News Provided by Canada Newswire via QuoteMedia

            This post appeared first on investingnews.com

            Several Democrat senators seemed ready to expand COVID-era Obamacare tax credits holding up spending legislation needed to reopen the government — but less willing to grapple with what that would mean for the country’s expenses.

            ‘I’ll disagree with the framing of deficit increase,’ Sen. Chris Coons, D-Del., said when asked about the program’s implications for the country’s bottom line.

            Others, like Sen. Alex Padilla, D-Calif., declined to respond.

            The country plunged into a shutdown at the beginning of the month when lawmakers failed to agree on a short-term spending extension that would have funded the government through Nov. 21. But the disagreement wasn’t about the package itself. In 2021, Congress temporarily expanded eligibility for Obamacare’s enhanced premium tax credits subsidies, meant to help Americans pay for their health insurance plans amid the uncertainty of the pandemic. That increased eligibility sunsets at the end of 2025. Democrats have made the program’s continuation a key condition in support for any spending package.

            Republicans need at least seven Democrats to advance spending legislation in the Senate, where Republicans must clear the 60-vote threshold to overcome a filibuster. The GOP holds 53 seats in the chamber.

            According to the Committee of a Responsible Federal Budget, a nonpartisan fiscal policy think tank, continuing the expanded credits could cost upwards of $30 billion annually.

            Where Republicans see the expiration as an opportunity to return government spending to pre-COVID levels and shrink the national deficit, Democrats have expressed alarm over recipients who could face an abrupt end to their federal assistance.

            ‘You have literally millions of Americans who will no longer be able to afford their health insurance or will be thrown off health insurance when the tax credits that make the Affordable Care Act affordable expire at the end of this year,’ Coons said, referring to the 2010 health care reforms that put Obamacare into law.

            Other Democrats pointed to healthcare as the key consideration at play.

            ‘Republicans need to restore healthcare to the American people. That’s my position,’ Sen. Mazie Hirono, D-Hawaii, said.

            Findings by KFF, a healthcare policy think tank, indicate that over 90% of the 24 million Obamacare enrollees make use of the enhanced credits.

            Democrats have voted against reopening the government 10 times since the start of the shutdown.

            Lawmakers like Sen. John Curtis, R-Utah, have pushed back on Democrat opposition, noting that the credits were always designed to be temporary — and that Democrats were the ones who included the sunset provision to begin with.

            ‘This is a pre-determined crisis by the Democrats,’ Curtis said. ‘They’re the ones who put the expiration date on these.’

            That’s also the position of Sen. John Boozman, R-Ark.

            ‘My concern is that [the credit expansion] was done during the pandemic, because of the pandemic. The pandemic is over. As a result, you’ve got people making $300,000 on a subsidy.’

            ‘So, what we need to do is get the government open, not hold the American people hostage and start talking, because there will be some people that are hurt,’ Boozman added.

            Boozman isn’t the only Republican concerned about both: ballooning government costs and the Americans who would have to adjust their payments to afford healthcare without the subsidies.

            Sen. Lisa Murkowski, R-Alaska, who has cautioned against sudden shifts to healthcare programs, said talks to advance both priorities haven’t made much progress. 

            ‘I’m trying to figure out a way that we can ensure that healthcare coverage for Americans remains, and we’re not making much headway this week,’ Murkowski said. 

            Other Senators hinted that talks were advancing in some way but declined to describe them.

            ‘I’m not getting engaged right now, because I may or may not be involved in any negotiations on what the ultimate resolution of this will be. At this point, until the Democrats open the government, I’m not going to discuss details,’ Sen. Mike Crapo, R-Idaho, said.

            Both chambers of Congress left Washington, D.C., for the weekend. The Senate will return Monday.

            This post appeared first on FOX NEWS